Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients
Latest Information Update: 12 Oct 2023
At a glance
- Drugs Celecoxib (Primary) ; Famotidine (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms LEAP-CT
- 05 Oct 2023 Planned End Date changed from 1 Jun 2024 to 1 Jan 2025.
- 05 Oct 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Jan 2025.
- 15 Aug 2022 Planned End Date changed from 1 Nov 2022 to 1 Jun 2024.